Please assess the completion status of the following clinical trial:

Trial Title: Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria (LRG):~Subjects must meet all of the following criteria at the time of subject ID assignment:~1. History of dog, cat, mongoose, fox, ferret, skunk, bat or raccoon bite to trunk, leg, ankle or foot, or lick or scratch with, or of broken skin or mucous membrane saliva or neural tissue contamination, unprotected physical bat contact, scratch or saliva contamination of the head or neck without broken skin all ≤ 54 hours (Section 3.9.4 and 3.9.5)~2. Has completed the written informed consent process and signed informed consent document~3. Males and females~4. Is age equal or more than 18 years on Study Day 1~5. Agrees to stay in contact with the study site for the duration of the study, provide updated contact information as necessary, and has no current plans to move from the study area for the duration of the study~6. Lives within 2 hour journey by available transportation to study center~7. For female subjects: agrees to avoid pregnancy from Study Day 1 through Study Day 121. Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses if menopausal) in sexual relationships with men must use an acceptable method of avoiding pregnancy during this period. Acceptable methods of avoiding pregnancy include a sterile sexual partner, sexual abstinence (not engaging in sexual intercourse), hormonal contraceptives (oral, injection, transdermal patch, or implant), vaginal ring, intrauterine device (IUD), or the combination of a condom or diaphragm with spermicide~Inclusion Criteria (NRG)~Subjects must meet all of the following criteria at the time of subject ID assignment:~1. History of dog, cat, mongoose, fox, ferret, skunk, bat or raccoon bite to any body part, lick or scratch with, or of broken skin, mucous membrane saliva or neural tissue contamination, or unprotected physical bat contact all ≤ 54 hours from PEP (Section 3.9.4 and 3.9.5)~2. Has completed the written informed consent process and signed informed consent document.~3. Males and females~4. Is age equal or more than 18 years on Study Day 1~5. Agrees to stay in contact with the study site for the duration of the study, provide updated contact information as necessary, and has no current plans to move from the study area for the duration of the study~6. Lives within 2 hour journey by available transportation to study center~7. For female subjects: agrees to avoid pregnancy from agrees to avoid pregnancy from Study Day 1 through Study Day 121. Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses if menopausal) in sexual relationships with men must use an acceptable method of avoiding pregnancy during this period. Acceptable methods of avoiding pregnancy include a sterile sexual partner, sexual abstinence (not engaging in sexual intercourse), hormonal contraceptives (oral, injection, transdermal patch, or implant), vaginal ring, intrauterine device (IUD), or the combination of a condom or diaphragm with spermicide~Exclusion Criteria:~Subjects must have had none of the following at the time of subject ID assignment:~1. Clinical evidence of rabies infection~2. Category 3 exposure \> 54 hours before Study Drug receipt~3. History or serological evidence of previous rabies vaccination~4. Previous receipt of equine or human rabies globulin~5. History of hypersensitivity reaction to equine or human immunoglobulin.~6. Received immunoglobulin or blood products within 42 days before Study Day 1~7. Received any investigational drug therapy or investigational vaccine within 60 days before Study Day 1~8. Planned participation in any other investigational study during the study period.~9. Receiving systemic immunosuppressant medication such as systemic corticosteroids but not limited to systemic corticosteroids~10. History or laboratory evidence of any past, present, or possible immunodeficiency state including but not limited to any laboratory indication of HIV infection~11. Previous medical history that may compromise the safety of the subject in the study according to the opinion of the principal investigator~12. History or evidence on physical examination of any systemic disease or any acute or chronic illness that, in the opinion of the investigator, may interfere with the evaluation of the safety or activity of SYN023~13. Pregnancy (results of the urine pregnancy test MUST be known before enrollment)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SYN023+Rabies vaccine (Type: EXPERIMENTAL): SYN023:~* Interventions: are administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible~* SYN023 is an equal mass mixture of CTB011 and CTB012, two monoclonal antibodies that exhibit a wide spectrum of activity against various wild-type rabies strains in vitro.~* Dosage form: 6mg/2mL, liquid,~* Dosage: 0.3 mg/kg of SYN023~* Frequency/duration: at Day 1~Rabies vaccine (RabAvert/Rabipur):~* Interventions: should be administered in deltoid muscle~* Dosage form: \>=2.5 IU, freeze-dried vaccine, reconstitute into 1mL before use~* Dosage: 1 mL after reconstitution~* Frequency/duration: at Day 1, 4, 8, 15, 29
- HRIG+Rabies vaccine (Type: ACTIVE_COMPARATOR): HRIG:~* Interventions: are administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible~* Dosage form: 150 IU/mL or 300 IU/mL, liquid,~* Dosage: 20 IU/kg of HyperRab (HRIG)~* Frequency/duration: at Day 1~Rabies vaccine (RabAvert/Rabipur):~* Interventions: should be administered in deltoid muscle~* Dosage form: \>=2.5 IU, freeze-dried vaccine, reconstitute into 1mL before use~* Dosage: 1 mL after reconstitution~* Frequency/duration: at Day 1, 4, 8, 15, 29

Based on this trial design, predict the completion outcome and termination type (if applicable).